Many immunomodulators, such as indoleamine 2,3‐dioxygenase (IDO) inhibitors, STAT3 inhibitors, TGF‐β inhibitors, CD137 agonists, and CD27 agonists, also have the potential to reshape the tumor immune microenvironment.[14] It remains unclear whether these immunomodulators play roles similar to those of R848 and aOX40, and further exploration is needed in the future to expand the strategic application of this work. This evidence concerns the gene STAT3 and neoplasm.